JP2017522307A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017522307A5 JP2017522307A5 JP2017501642A JP2017501642A JP2017522307A5 JP 2017522307 A5 JP2017522307 A5 JP 2017522307A5 JP 2017501642 A JP2017501642 A JP 2017501642A JP 2017501642 A JP2017501642 A JP 2017501642A JP 2017522307 A5 JP2017522307 A5 JP 2017522307A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- binding antagonist
- medicament
- raf
- axis binding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000005557 antagonist Substances 0.000 claims 62
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims 34
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims 34
- 239000003814 drug Substances 0.000 claims 34
- KKVYYGGCHJGEFJ-UHFFFAOYSA-N 1-n-(4-chlorophenyl)-6-methyl-5-n-[3-(7h-purin-6-yl)pyridin-2-yl]isoquinoline-1,5-diamine Chemical compound N=1C=CC2=C(NC=3C(=CC=CN=3)C=3C=4N=CNC=4N=CN=3)C(C)=CC=C2C=1NC1=CC=C(Cl)C=C1 KKVYYGGCHJGEFJ-UHFFFAOYSA-N 0.000 claims 25
- 101100381978 Mus musculus Braf gene Proteins 0.000 claims 25
- 206010028980 Neoplasm Diseases 0.000 claims 25
- 201000011510 cancer Diseases 0.000 claims 25
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 claims 24
- 229940124647 MEK inhibitor Drugs 0.000 claims 20
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 9
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims 9
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 claims 3
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 claims 3
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 claims 3
- 102200055464 rs113488022 Human genes 0.000 claims 3
- 101000984753 Homo sapiens Serine/threonine-protein kinase B-raf Proteins 0.000 claims 2
- 206010069755 K-ras gene mutation Diseases 0.000 claims 2
- -1 PLX-3603 Chemical compound 0.000 claims 2
- 102100027103 Serine/threonine-protein kinase B-raf Human genes 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 229960002465 dabrafenib Drugs 0.000 claims 2
- BFSMGDJOXZAERB-UHFFFAOYSA-N dabrafenib Chemical group S1C(C(C)(C)C)=NC(C=2C(=C(NS(=O)(=O)C=3C(=CC=CC=3F)F)C=CC=2)F)=C1C1=CC=NC(N)=N1 BFSMGDJOXZAERB-UHFFFAOYSA-N 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 239000003446 ligand Substances 0.000 claims 2
- 230000035772 mutation Effects 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000012453 solvate Substances 0.000 claims 2
- YABJJWZLRMPFSI-UHFFFAOYSA-N 1-methyl-5-[[2-[5-(trifluoromethyl)-1H-imidazol-2-yl]-4-pyridinyl]oxy]-N-[4-(trifluoromethyl)phenyl]-2-benzimidazolamine Chemical compound N=1C2=CC(OC=3C=C(N=CC=3)C=3NC(=CN=3)C(F)(F)F)=CC=C2N(C)C=1NC1=CC=C(C(F)(F)F)C=C1 YABJJWZLRMPFSI-UHFFFAOYSA-N 0.000 claims 1
- 108091023037 Aptamer Proteins 0.000 claims 1
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- DEZZLWQELQORIU-RELWKKBWSA-N GDC-0879 Chemical compound N=1N(CCO)C=C(C=2C=C3CCC(/C3=CC=2)=N\O)C=1C1=CC=NC=C1 DEZZLWQELQORIU-RELWKKBWSA-N 0.000 claims 1
- 102100030708 GTPase KRas Human genes 0.000 claims 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims 1
- 101000584612 Homo sapiens GTPase KRas Proteins 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 239000005511 L01XE05 - Sorafenib Substances 0.000 claims 1
- 241000023320 Luma <angiosperm> Species 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- YZDJQTHVDDOVHR-UHFFFAOYSA-N PLX-4720 Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(Cl)=CN=C3NC=2)=C1F YZDJQTHVDDOVHR-UHFFFAOYSA-N 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 230000003213 activating effect Effects 0.000 claims 1
- 229940125528 allosteric inhibitor Drugs 0.000 claims 1
- 229960003852 atezolizumab Drugs 0.000 claims 1
- 229950002916 avelumab Drugs 0.000 claims 1
- BSMCAPRUBJMWDF-KRWDZBQOSA-N cobimetinib Chemical compound C1C(O)([C@H]2NCCCC2)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F BSMCAPRUBJMWDF-KRWDZBQOSA-N 0.000 claims 1
- 229960002271 cobimetinib Drugs 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 230000008878 coupling Effects 0.000 claims 1
- 238000010168 coupling process Methods 0.000 claims 1
- 238000005859 coupling reaction Methods 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- HXINDCTZKGGRDE-JPKZNVRTSA-L disodium;[3-[5-[2-[[(3r)-1-(1-methylpyrazol-3-yl)sulfonylpiperidin-3-yl]amino]pyrimidin-4-yl]imidazo[2,1-b][1,3]oxazol-6-yl]phenoxy]methyl phosphate Chemical compound [Na+].[Na+].CN1C=CC(S(=O)(=O)N2C[C@@H](CCC2)NC=2N=C(C=CN=2)C=2N3C=COC3=NC=2C=2C=C(OCOP([O-])([O-])=O)C=CC=2)=N1 HXINDCTZKGGRDE-JPKZNVRTSA-L 0.000 claims 1
- 229950009791 durvalumab Drugs 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 238000002513 implantation Methods 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 230000001394 metastastic effect Effects 0.000 claims 1
- 206010061289 metastatic neoplasm Diseases 0.000 claims 1
- MMNNTJYFHUDSKL-UHFFFAOYSA-N methyl n-[6-[2-(5-chloro-2-methylphenyl)-1-hydroxy-3-oxoisoindol-1-yl]-1h-benzimidazol-2-yl]carbamate Chemical compound C=1C=C2NC(NC(=O)OC)=NC2=CC=1C(C1=CC=CC=C1C1=O)(O)N1C1=CC(Cl)=CC=C1C MMNNTJYFHUDSKL-UHFFFAOYSA-N 0.000 claims 1
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 claims 1
- 210000003928 nasal cavity Anatomy 0.000 claims 1
- 229960003301 nivolumab Drugs 0.000 claims 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 229960002621 pembrolizumab Drugs 0.000 claims 1
- 239000000816 peptidomimetic Substances 0.000 claims 1
- 108091033319 polynucleotide Proteins 0.000 claims 1
- 102000040430 polynucleotide Human genes 0.000 claims 1
- 239000002157 polynucleotide Substances 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 229960004836 regorafenib Drugs 0.000 claims 1
- FNHKPVJBJVTLMP-UHFFFAOYSA-N regorafenib Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=C(F)C(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 FNHKPVJBJVTLMP-UHFFFAOYSA-N 0.000 claims 1
- 150000003384 small molecules Chemical group 0.000 claims 1
- 229960003787 sorafenib Drugs 0.000 claims 1
- 229950007213 spartalizumab Drugs 0.000 claims 1
- 229940124530 sulfonamide Drugs 0.000 claims 1
- 230000002459 sustained effect Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- GPXBXXGIAQBQNI-UHFFFAOYSA-N vemurafenib Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(=CN=C3NC=2)C=2C=CC(Cl)=CC=2)=C1F GPXBXXGIAQBQNI-UHFFFAOYSA-N 0.000 claims 1
- 229960003862 vemurafenib Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462024988P | 2014-07-15 | 2014-07-15 | |
| US62/024,988 | 2014-07-15 | ||
| PCT/US2015/040582 WO2016011160A1 (en) | 2014-07-15 | 2015-07-15 | Compositions for treating cancer using pd-1 axis binding antagonists and mek inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019210780A Division JP2020059721A (ja) | 2014-07-15 | 2019-11-21 | Ｐｄ−１軸結合アンタゴニスト及びｍｅｋ阻害剤を使用した癌を処置するための組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017522307A JP2017522307A (ja) | 2017-08-10 |
| JP2017522307A5 true JP2017522307A5 (cg-RX-API-DMAC7.html) | 2018-08-23 |
| JP6673896B2 JP6673896B2 (ja) | 2020-03-25 |
Family
ID=53783950
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017501642A Active JP6673896B2 (ja) | 2014-07-15 | 2015-07-15 | Ｐｄ−１軸結合アンタゴニスト及びｍｅｋ阻害剤を使用した癌を処置するための組成物 |
| JP2019210780A Pending JP2020059721A (ja) | 2014-07-15 | 2019-11-21 | Ｐｄ−１軸結合アンタゴニスト及びｍｅｋ阻害剤を使用した癌を処置するための組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019210780A Pending JP2020059721A (ja) | 2014-07-15 | 2019-11-21 | Ｐｄ−１軸結合アンタゴニスト及びｍｅｋ阻害剤を使用した癌を処置するための組成物 |
Country Status (17)
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI835048B (zh) | 2011-08-01 | 2024-03-11 | 美商建南德克公司 | 利用pd-1軸結合拮抗劑及mek抑制劑治療癌症之方法 |
| US10441654B2 (en) | 2014-01-24 | 2019-10-15 | Children's Hospital Of Eastern Ontario Research Institute Inc. | SMC combination therapy for the treatment of cancer |
| WO2016011160A1 (en) | 2014-07-15 | 2016-01-21 | Genentech, Inc. | Compositions for treating cancer using pd-1 axis binding antagonists and mek inhibitors |
| GB201506411D0 (en) | 2015-04-15 | 2015-05-27 | Bergenbio As | Humanized anti-axl antibodies |
| WO2017011580A2 (en) | 2015-07-13 | 2017-01-19 | Cytomx Therapeutics, Inc. | Anti-pd-1 antibodies, activatable anti-pd-1 antibodies, and methods of use thereof |
| KR20180097615A (ko) | 2016-01-08 | 2018-08-31 | 에프. 호프만-라 로슈 아게 | Pd-1 축 결합 길항물질 및 항-cea/항-cd3 이중특이성 항체를 사용하는 cea-양성 암의 치료 방법 |
| PL3439653T3 (pl) * | 2016-04-07 | 2021-07-05 | Chemocentryx, Inc. | Zmniejszenie obciążenia guzem przez podawanie antagonistów ccr1 w skojarzeniu z inhibitorami pd-1 lub inhibitorami pd-l1 |
| WO2017202744A1 (en) * | 2016-05-26 | 2017-11-30 | Merck Patent Gmbh | Pd-1 / pd-l1 inhibitors for cancer treatment |
| BR112018075371A2 (pt) * | 2016-06-10 | 2019-03-19 | Novartis Ag | usos terapêuticos de um inibidor de c-raf |
| CN110072553B (zh) * | 2016-12-22 | 2023-09-15 | 豪夫迈·罗氏有限公司 | 在抗pd-l1/pd1治疗失败之后抗csf-1r抗体与抗pd-l1抗体组合对肿瘤的治疗 |
| US11040027B2 (en) | 2017-01-17 | 2021-06-22 | Heparegenix Gmbh | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
| CN108503691B (zh) * | 2017-02-25 | 2021-07-23 | 复旦大学 | 一种人pd-l1蛋白高亲和性肽及其应用 |
| PL3612234T3 (pl) | 2017-04-20 | 2024-09-02 | Adc Therapeutics Sa | Terapia skojarzona z koniugatem anty-AXL przeciwciało-lek |
| CN110582303A (zh) | 2017-04-20 | 2019-12-17 | Adc治疗有限公司 | 使用抗cd25抗体-药物缀合物的组合疗法 |
| IL270948B2 (en) | 2017-06-02 | 2025-07-01 | Bayer Ag | Combination of regorafenib and pd-1/pd-l1(2) inhibitors for treating cancer |
| BR112019026564A2 (pt) | 2017-06-14 | 2020-06-30 | Adc Therapeutics Sa | regimes de dosagem para a administração de um adc anti-cd19 |
| WO2019023786A1 (en) * | 2017-08-01 | 2019-02-07 | University Health Network | COMBINED THERAPIES FOR THE INHIBITION OF TTK PROTEIN KINASE |
| MX2020003361A (es) * | 2017-10-13 | 2020-07-29 | Merck Patent Gmbh | Combinacion de un inhibidor parp y un antagonista de union al eje pd-1. |
| KR20200106921A (ko) * | 2018-01-10 | 2020-09-15 | 어레이 바이오파마 인크. | 암을 치료하기 위한 방법 및 조합 요법 |
| KR20210016562A (ko) | 2018-05-23 | 2021-02-16 | 에이디씨 테라퓨틱스 에스에이 | 분자 애쥬번트 |
| JP2022502074A (ja) * | 2018-09-10 | 2022-01-11 | ジェネセイル バイオテック（シャンハイ）カンパニー リミテッド | 改変された腫瘍溶解性ウイルス、組成物、およびその使用 |
| CN109053891B (zh) * | 2018-09-17 | 2021-12-21 | 苏州泓迅生物科技股份有限公司 | 一种抗pd-l1抗体及其制备方法和应用 |
| CN109879855B (zh) * | 2019-03-26 | 2021-01-05 | 中国医学科学院医药生物技术研究所 | 靶向肿瘤细胞表面pd-l1分子的抑制剂及其应用 |
| GB201917254D0 (en) | 2019-11-27 | 2020-01-08 | Adc Therapeutics Sa | Combination therapy |
| CN110981943B (zh) * | 2019-12-02 | 2021-08-03 | 清华大学 | 多肽及其在制备药物中的用途和药物 |
| EP4178573A4 (en) * | 2020-07-13 | 2024-08-07 | Verastem, Inc. | COMBINATION THERAPY FOR THE TREATMENT OF ABNORMAL CELL GROWTH |
| GB202102396D0 (en) | 2021-02-19 | 2021-04-07 | Adc Therapeutics Sa | Molecular adjuvant |
| US20250281607A1 (en) * | 2021-07-27 | 2025-09-11 | Toray Industries, Inc. | Medicament for treatment and/or prevention of cancer |
Family Cites Families (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1247080A (en) | 1983-03-08 | 1988-12-20 | Commonwealth Serum Laboratories Commission | Antigenically active amino acid sequences |
| WO1984003506A1 (en) | 1983-03-08 | 1984-09-13 | Commw Serum Lab Commission | Antigenically active amino acid sequences |
| NZ207394A (en) | 1983-03-08 | 1987-03-06 | Commw Serum Lab Commission | Detecting or determining sequence of amino acids |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| NZ215865A (en) | 1985-04-22 | 1988-10-28 | Commw Serum Lab Commission | Method of determining the active site of a receptor-binding analogue |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| US5571689A (en) | 1988-06-16 | 1996-11-05 | Washington University | Method of N-acylating peptide and proteins with diheteroatom substituted analogs of myristic acid |
| US5663143A (en) | 1988-09-02 | 1997-09-02 | Dyax Corp. | Engineered human-derived kunitz domains that inhibit human neutrophil elastase |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5225538A (en) | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| DE69133566T2 (de) | 1990-01-12 | 2007-12-06 | Amgen Fremont Inc. | Bildung von xenogenen Antikörpern |
| AU663053B2 (en) | 1990-06-11 | 1995-09-28 | Gilead Sciences, Inc. | Nucleic acid ligands |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| WO1992003918A1 (en) | 1990-08-29 | 1992-03-19 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| AU668347B2 (en) | 1990-11-21 | 1996-05-02 | Torrey Pines Institute For Molecular Studies | Synthesis of equimolar multiple oligomer mixtures, especially of oligopeptide mixtures |
| DK0564531T3 (da) | 1990-12-03 | 1998-09-28 | Genentech Inc | Berigelsesfremgangsmåde for variantproteiner med ændrede bindingsegenskaber |
| DK1136556T3 (da) | 1991-11-25 | 2005-10-03 | Enzon Inc | Fremgangsmåde til fremstilling af multivalente antigen-bindende proteiner |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| ATE390933T1 (de) | 1995-04-27 | 2008-04-15 | Amgen Fremont Inc | Aus immunisierten xenomäusen stammende menschliche antikörper gegen il-8 |
| WO1996034096A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| CA2722378C (en) | 1996-12-03 | 2015-02-03 | Amgen Fremont Inc. | Human antibodies that bind tnf.alpha. |
| EP1034298B1 (en) | 1997-12-05 | 2011-11-02 | The Scripps Research Institute | Humanization of murine antibody |
| AU8856201A (en) | 2000-09-01 | 2002-03-13 | Andel Inst Van | Inhibition of mitogen-activated protein kinase (mapk) pathway: a selective therapeutic strategy against melanoma |
| IL149462A0 (en) | 2001-05-09 | 2002-11-10 | Warner Lambert Co | Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor |
| TWI350285B (en) | 2002-03-13 | 2011-10-11 | Array Biopharma Inc | N3 alkylated benzimidazole derivatives as mek inhibitors |
| US20040209930A1 (en) | 2002-10-02 | 2004-10-21 | Carboni Joan M. | Synergistic methods and compositions for treating cancer |
| US7217797B2 (en) | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| CA2502413A1 (en) | 2002-11-01 | 2004-05-21 | The Regents Of The University Of Colorado, A Body Corporate | Quantitative analysis of protein isoforms using matrix-assisted laser desorption/ionization time of flight mass spectrometry |
| CA2506085A1 (en) | 2002-11-15 | 2004-06-03 | Ronald Lynn Merriman | Combination chemotherapy comprising a mek inhibitor and capecitabine for treating cancer |
| RS50569B (sr) | 2004-06-11 | 2010-05-07 | Japan Tobacco Inc. | Derivati 5-amino-2,4,7-triokso-3,4,7,8-tetrahidro-2h-pirido (2,3-d)pirimidina i slična jedinjenja za lečenje raka |
| TW200639163A (en) | 2005-02-04 | 2006-11-16 | Genentech Inc | RAF inhibitor compounds and methods |
| EP1896582A4 (en) | 2005-05-09 | 2009-04-08 | Ono Pharmaceutical Co | HUMAN MONOCLONAL ANTIBODIES AGAINST PROGRAMMED CELL DEATH 1 (PD-1) AND METHOD FOR CREATING TREATMENT WITH ANTI-PD-1 ANTIBODIES ALONE OR IN COMBINATION WITH OTHER IMMUNOTHERAPEUTICS |
| CN102603581B (zh) | 2005-06-22 | 2015-06-24 | 普莱希科公司 | 作为蛋白质激酶抑制剂的吡咯并[2,3-b]吡啶衍生物 |
| CN104356236B (zh) | 2005-07-01 | 2020-07-03 | E.R.施贵宝&圣斯有限责任公司 | 抗程序性死亡配体1(pd-l1)的人单克隆抗体 |
| CA2622755C (en) | 2005-10-07 | 2017-01-31 | Exelixis, Inc. | Azetidines as mek inhibitors |
| US7612212B2 (en) | 2006-02-22 | 2009-11-03 | Hoffmann-La Roche Inc. | Substituted hydantoins |
| AU2007286808B2 (en) | 2006-08-21 | 2012-12-06 | Genentech, Inc. | Aza-benzofuranyl compounds and methods of use |
| WO2008101840A1 (en) | 2007-02-23 | 2008-08-28 | F. Hoffmann-La Roche Ag | Combination of erlotinib and mek-inhibitors for inhibiting proliferation of tumor cells |
| EP2188276B1 (en) | 2007-08-16 | 2012-03-28 | F. Hoffmann-La Roche AG | Substituted hydantoins |
| WO2009064675A1 (en) | 2007-11-12 | 2009-05-22 | Takeda Pharmaceutical Company Limited | Mapk/erk kinase inhibitors |
| AR069747A1 (es) | 2007-11-30 | 2010-02-17 | Medarex Inc | Conjugado anticuerpo monoclonal anti-b7h4- farmaco y metodos de utilizacion |
| AR069803A1 (es) | 2007-12-19 | 2010-02-17 | Genentech Inc | 5- anilinoimiazopiridinas y metodos de uso |
| BRPI0907718A2 (pt) | 2008-02-11 | 2017-06-13 | Curetech Ltd | método para tratar um tumor, método para melhorar a tolerabilidade a pelo menos um agente quimiterápico, método para aumentar a sobrevida de um indivíduo que tem um tumor, método para reduzir ou prevenir recidiva tumoral, uso de um anticorpo monoclonal humanizado ou seu fragmento e anticorpo monoclonal humanizado ou seu fragmento |
| TW200940539A (en) | 2008-02-29 | 2009-10-01 | Array Biopharma Inc | RAF inhibitor compounds and methods of use thereof |
| EP2265574A1 (en) | 2008-02-29 | 2010-12-29 | Array Biopharma, Inc. | N- (6-aminopyridin-3-yl) -3- (sulfonamido) benzamide derivatives as b-raf inhibitors for the treatment of cancer |
| WO2009111278A2 (en) | 2008-02-29 | 2009-09-11 | Array Biopharma Inc. | Raf inhibitor compounds and methods of use thereof |
| US20110003809A1 (en) | 2008-02-29 | 2011-01-06 | Array Biopharma Inc. | Imidazo [4,5-b] pyridine derivatives used as raf inhibitors |
| WO2009114335A2 (en) | 2008-03-12 | 2009-09-17 | Merck & Co., Inc. | Pd-1 binding proteins |
| CA2729914A1 (en) | 2008-07-11 | 2010-01-14 | Novartis Ag | Combination of (a) a phosphoinositide 3-kinase inhibitor and (b) a modulator of ras/raf/mek pathway |
| EP2328919A2 (en) | 2008-08-25 | 2011-06-08 | Amplimmune, Inc. | Pd-i antagonists and methods for treating infectious disease |
| EP2350129B1 (en) | 2008-08-25 | 2015-06-10 | Amplimmune, Inc. | Compositions of pd-1 antagonists and methods of use |
| WO2010056735A1 (en) | 2008-11-11 | 2010-05-20 | The Trustees Of The University Of Pennsylvania | Compositions and methods for inhibiting an oncogenic protein to enhance immunogenicity |
| TW202442680A (zh) | 2008-12-09 | 2024-11-01 | 美商建南德克公司 | 抗pd-l1抗體及其於增進t細胞功能之用途 |
| PE20121816A1 (es) | 2009-10-12 | 2013-01-02 | Hoffmann La Roche | Combinaciones de un inhibidor de pi3k y un inhibidor de mek |
| EP2501237A1 (en) | 2009-11-06 | 2012-09-26 | Infinity Pharmaceuticals, Inc. | Oral formulations of a hedgehog pathway inhibitor |
| JP2013510585A (ja) | 2009-11-13 | 2013-03-28 | インフィニティー ファーマシューティカルズ， インコーポレイテッド | 癌の同定、評価、予防および治療のための組成物、キットおよび方法 |
| WO2011066342A2 (en) | 2009-11-24 | 2011-06-03 | Amplimmune, Inc. | Simultaneous inhibition of pd-l1/pd-l2 |
| MX343747B (es) | 2009-11-24 | 2016-11-22 | Medimmune Ltd | Agentes de union diana contra b7-h1. |
| EP2982380B1 (en) | 2010-03-04 | 2021-09-01 | MacroGenics, Inc. | Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof |
| TWI835048B (zh) * | 2011-08-01 | 2024-03-11 | 美商建南德克公司 | 利用pd-1軸結合拮抗劑及mek抑制劑治療癌症之方法 |
| SG11201401815XA (en) | 2011-10-28 | 2014-05-29 | Genentech Inc | Therapeutic combinations and methods of treating melanoma |
| EP2970474B1 (en) | 2013-03-14 | 2017-12-20 | Genentech, Inc. | Anti-b7-h4 antibodies and immunoconjugates |
| US9308236B2 (en) | 2013-03-15 | 2016-04-12 | Bristol-Myers Squibb Company | Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions |
| BR112015028326A8 (pt) | 2013-06-03 | 2018-01-23 | Novartis Ag | combinações de anticorpo anti-pd-l1, inibidor de mek e/ou inibidor de braf, seus kits e seus usos, e composição farmacêutica |
| WO2016011160A1 (en) | 2014-07-15 | 2016-01-21 | Genentech, Inc. | Compositions for treating cancer using pd-1 axis binding antagonists and mek inhibitors |
-
2015
- 2015-07-15 WO PCT/US2015/040582 patent/WO2016011160A1/en not_active Ceased
- 2015-07-15 KR KR1020177003776A patent/KR20170026630A/ko not_active Ceased
- 2015-07-15 CN CN201580030345.4A patent/CN106573060A/zh active Pending
- 2015-07-15 ES ES15747647T patent/ES2742500T3/es active Active
- 2015-07-15 AR ARP150102249A patent/AR101210A1/es unknown
- 2015-07-15 SG SG11201700074YA patent/SG11201700074YA/en unknown
- 2015-07-15 AU AU2015289672A patent/AU2015289672A1/en not_active Abandoned
- 2015-07-15 PL PL15747647T patent/PL3169361T3/pl unknown
- 2015-07-15 JP JP2017501642A patent/JP6673896B2/ja active Active
- 2015-07-15 SG SG10202007111TA patent/SG10202007111TA/en unknown
- 2015-07-15 BR BR112017000672A patent/BR112017000672A2/pt not_active Application Discontinuation
- 2015-07-15 EP EP15747647.4A patent/EP3169361B1/en active Active
- 2015-07-15 EP EP19172991.2A patent/EP3563870A1/en not_active Withdrawn
- 2015-07-15 MX MX2017000546A patent/MX2017000546A/es unknown
- 2015-07-15 RU RU2017102926A patent/RU2733735C2/ru active
- 2015-07-15 CN CN202310512479.6A patent/CN116617401A/zh active Pending
- 2015-07-15 CA CA2954508A patent/CA2954508A1/en not_active Abandoned
-
2017
- 2017-01-05 US US15/399,118 patent/US10946093B2/en active Active
- 2017-01-10 IL IL250021A patent/IL250021B/en active IP Right Grant
- 2017-02-14 ZA ZA2017/01109A patent/ZA201701109B/en unknown
-
2019
- 2019-11-21 JP JP2019210780A patent/JP2020059721A/ja active Pending
-
2020
- 2020-07-27 IL IL276314A patent/IL276314A/en unknown
-
2021
- 2021-02-11 US US17/174,019 patent/US20220105180A1/en not_active Abandoned
-
2024
- 2024-01-31 US US18/429,055 patent/US20240390488A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017522307A5 (cg-RX-API-DMAC7.html) | ||
| RU2017102926A (ru) | Композиции для лечения рака с применением антагонистов, связывающихся с компонентом сигнального пути pd-1, и ингибиторов мек | |
| JP2017537090A5 (cg-RX-API-DMAC7.html) | ||
| JP6774421B2 (ja) | がんの治療のための方法、組成物、及びキット | |
| CN110536905B (zh) | 用于治疗肺癌的抗pd-1抗体 | |
| JP2017501167A5 (cg-RX-API-DMAC7.html) | ||
| JP2023098947A5 (cg-RX-API-DMAC7.html) | ||
| RU2017133273A (ru) | Ингибиторы pd-1 / pd-l1 для лечения рака | |
| RU2017121096A (ru) | Комбинированная терапия, включающая применение ох40-связывающих агонистов и антагонистов связывания оси pd-1 | |
| JP2018070648A5 (cg-RX-API-DMAC7.html) | ||
| JP2017533912A5 (cg-RX-API-DMAC7.html) | ||
| JP2017514795A5 (cg-RX-API-DMAC7.html) | ||
| TW201922793A (zh) | Ｐｄ－１抗體和ｖｅｇｆｒ抑制劑聯合治療小細胞肺癌的用途 | |
| RU2018146812A (ru) | Фармацевтические комбинации | |
| JP2020511408A5 (cg-RX-API-DMAC7.html) | ||
| JP2019525948A5 (cg-RX-API-DMAC7.html) | ||
| JP2024007504A (ja) | Ｋｒａｓ ｇ１２ｃ阻害剤の投与レジメン | |
| US20220152029A1 (en) | Methods and compositions comprising a krasg12c inhibitor and a pd-l1 binding antagonist for treating lung cancer | |
| JP2019517507A (ja) | 特定の癌の治療のためのラムシルマブとペンブロリズマブとの組み合わせ | |
| CN115052628A (zh) | 抗pd-1抗体在治疗肿瘤中的用途 | |
| AU2021397214B2 (en) | Methods and compositions comprising a krasg12c inhibitor and a egfr-inhibitor for treating solid tumors | |
| TWI886356B (zh) | 用於治療實性瘤之方法與包含ｋｒａｓｇ１２ｃ抑制劑及ｖｅｇｆ抑制劑之組成物 | |
| TWI870592B (zh) | 使用免疫檢查點抑制劑抗體治療癌症之方法和組合 | |
| CN113473989B (zh) | Sumo活化酶抑制剂和检查点抑制剂的施用 | |
| WO2021213523A1 (zh) | 抗pd-1抗体和抗ctla-4抗体的组合在预防或治疗癌症中的用途 |